Abstract：
OBJECTIVE:To review, summarize, and analyze both similarities and differences of pharmacoeconomic (PE) guidelines, to enable researchers to access their characteristics and the current state of PE guidelines; furthermore, to learn which methodological issues still remain contested and to promote the methodological development of PE guidelines. MATERIALS AND METHODS:The authors performed a search for PE guidelines using PubMed, the Cochrane library database, and the websites of the International Society for Pharmacoeconomics and Outcomes Research. Information of each guideline was extracted using a pre-designed extraction template, which included 22 aspects; the guidelines were summarized in the forms of charts, and their characteristics have been described. RESULTS:A total of 40 PE guidelines were studied. The most common methodological issues include the types of analysis, sources for effectiveness, use of quality-adjusted life-years (QALYs) to measure outcomes, and use of incremental cost effectiveness ratios to present results. The majority of the guidelines preferred a cost utility analysis with outcomes expressed in terms of QALYs. Most of the guidelines preferred meta-analysis or meta-analysis of the randomized controlled trials, and required a systematic review of all evidence. Issues that varied most in the guidelines were the choice of the comparator, recommended costs to be included, methods related to indirect cost calculations, methods of sensitivity analysis, and discounting rate. CONCLUSION:A comparison of these guidelines revealed that a number of differences exist among them in several key aspects, and some critical methodological issues still exist, for which no best solution is available. Furthermore, efforts need to be made to develop harmonious methods for the PE, and to improve the transferability of the outcomes of PE evaluations.
journal_name
J Med Econjournal_title
Journal of medical economicsauthors
Zhao Y,Feng HM,Qu J,Luo X,Ma WJ,Tian JHdoi
10.1080/13696998.2017.1387118subject
Has Abstractpub_date
2018-01-01 00:00:00pages
85-96issue
1eissn
1369-6998issn
1941-837Xjournal_volume
21pub_type
杂志文章,评审abstract：INTRODUCTION:Triple therapy using a protease inhibitor (PI) with peginterferon and ribavirin (PR) is increasingly used in patients with chronic hepatitis C virus (HCV) infection. The most recently introduced PI, simeprevir (SMV), offers high levels of viral eradication combined with a reduced overall duration of therap...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1044457
更新日期：2015-01-01 00:00:00
abstract：OBJECTIVE:To quantify the health economic impact of managing cow milk allergy (CMA) in South Africa, from the perspective of healthcare insurers in both the private and public sectors and parents/carers of CMA sufferers. METHODS:A decision model depicting the management of CMA in South Africa was constructed, using in...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2010.482904
更新日期：2010-01-01 00:00:00
abstract：OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...
journal_title：Journal of medical economics
pub_type： 杂志文章,随机对照试验
doi：10.3111/13696998.2013.770747
更新日期：2013-01-01 00:00:00
abstract：AIMS:The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and healthcare costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently init...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2017.1363766
更新日期：2017-12-01 00:00:00
abstract：OBJECTIVE:This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective. METHODS:An analysis was conducted from a US health plan perspective to comp...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990801959656
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients w...
journal_title：Journal of medical economics
pub_type： 评论,社论
doi：10.3111/13696998.2015.1073736
更新日期：2015-01-01 00:00:00
abstract：BACKGROUND:A Phase-3 study of defibrotide compared with historical controls demonstrated a 23% improvement in 100-day survival post-hematopoietic stem cell transplantation (HSCT) among patients with veno-occlusive disease with multi-organ dysfunction (VOD with MOD). AIM:To estimate the budget impact and cost-effective...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2016.1275652
更新日期：2017-05-01 00:00:00
abstract：OBJECTIVES:Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second in...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.729549
更新日期：2013-01-01 00:00:00
abstract：INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1032974
更新日期：2015-01-01 00:00:00
abstract：OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2018.1551226
更新日期：2018-11-21 00:00:00
abstract：OBJECTIVE:To estimate the cost-effectiveness of ipilimumab (3 mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. METHODS:The analysis was based on a US payer perspective and lifetime time horizon. A three-state Markov model was developed representing clinical outcomes, quality-o...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.739226
更新日期：2013-01-01 00:00:00
abstract：OBJECTIVE:To estimate the annualized differences in direct medical and indirect costs associated with improvement in fibromyalgia (FM) severity among pregabalin-treated patients. METHODS:Data from three clinical trials of pregabalin in patients with FM were modeled; efficacy results were extrapolated. Mean annual cost...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.727930
更新日期：2013-01-01 00:00:00
abstract：OBJECTIVE:To compare rates of severe relapse and total direct and indirect costs over a 2-year period between US-based employees with multiple sclerosis (MS) who were adherent and non-adherent to disease-modifying drugs (DMDs). METHODS:Employees with ≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim between ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.667027
更新日期：2012-01-01 00:00:00
abstract：OBJECTIVES:The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses. METHODS:Data fr...
journal_title：Journal of medical economics
pub_type： 杂志文章,随机对照试验
doi：10.3111/13696990903438617
更新日期：2009-01-01 00:00:00
abstract：OBJECTIVE:To compare outcomes between patients with type 2 diabetes mellitus (T2DM) using fixed-dose combination (FDC) and loose-dose combination (LDC) products. METHODS:This retrospective cohort study used MarketScan Commercial and Medicare Supplemental data from January 1, 2009-December 31, 2013. The identified popu...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1109518
更新日期：2016-01-01 00:00:00
abstract：OBJECTIVE:The aim of this study was to evaluate medication adherence and persistence of patients treated with Etanercept and Adalimumab for Rheumatoid Arthritis, also giving economic evaluations on therapy costs for Received Daily Dose (RDD). MATERIALS AND METHODS:This retrospective study took into account 6 years fro...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2014.902844
更新日期：2014-05-01 00:00:00
abstract：OBJECTIVE:The use of hemostatic agents has increased over time for all surgical procedures. The purpose of this study was to evaluate the newer topical absorbable hemostat products Surgicel * Fibrillar † and Surgicel SNoW ‡ (Surgicel advanced products, abbreviated as SAPs) compared to the older product Surgicel Origina...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1017503
更新日期：2015-06-01 00:00:00
abstract：:Objective: To estimate the cost-effectiveness of utidelone plus capecitabine therapy compared to capecitabine alone in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes treatment in the Chinese context and provide a reference for the marketing of utidelone in China. Methods: A Markov...
journal_title：Journal of medical economics
pub_type： 杂志文章,随机对照试验
doi：10.1080/13696998.2019.1588125
更新日期：2019-06-01 00:00:00
abstract：:Aims: Nocturia (getting up at night to urinate, where each urination being followed by sleep or intention to sleep) is a bothersome symptom with potentially negative consequences for individual health and daytime functioning. This study assessed the burden of nocturia in the workplace by investigating associations bet...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1767631
更新日期：2020-09-01 00:00:00
abstract：OBJECTIVES:To evaluate the economic burden of herpes zoster (HZ) on the US healthcare system among an immunocompetent population. METHODS:Claims data from the MarketScan Research databases for 2008-2011 were extracted to determine the incremental healthcare resource utilization (RU) and direct medical costs associated...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2016.1187150
更新日期：2016-10-01 00:00:00
abstract：OBJECTIVE:A cost analysis of once-daily insulin glargine versus three-times daily insulin lispro in combination with oral antidiabetic drugs (OADs) for insulin-naive type 2 diabetes patients in Germany based on the APOLLO trial (A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantu...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990902949614
更新日期：2009-06-01 00:00:00
abstract：OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1571500
更新日期：2019-04-01 00:00:00
abstract：BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.761633
更新日期：2013-01-01 00:00:00
abstract：OBJECTIVES:The purpose of this study is to report on long-term treatment patterns in a back pain population and to consider whether these may be considered as reflective of under-treatment of pain or poor pain control. METHODS:Data are from a commissioned recontact SELECT survey of persons who had previously reported ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2013.777346
更新日期：2013-01-01 00:00:00
abstract：:Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model w...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1688819
更新日期：2020-02-01 00:00:00
abstract：PURPOSE:The Czech Republic is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. A pharmacoeconomic analysis was conducted to determine the cost-effectiveness of atypical depots. METHODS:An existing 1-year decision-analytic framework was adapted to model drug use in t...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2013.820193
更新日期：2013-09-01 00:00:00
abstract：BACKGROUND:Approximately 20-30% of Canadians suffer from chronic pain. Guidelines for the management of chronic pain support the use of controlled-release (CR) opioids to treat chronic pain. Although effective in managing chronic pain, oxycodone is associated with high rates of opioid-induced constipation (OIC). The co...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1116992
更新日期：2016-01-01 00:00:00
abstract：:Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1754229
更新日期：2020-08-01 00:00:00
abstract：AIMS:Patients with psoriasis often undergo treatment with a sequence of biologic agents because of poor/loss of response to initial therapy. With the availability of newer agents like ixekizumab and secukinumab, there is a need for cost-effectiveness analyses to better reflect current clinical practice. This study aime...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2018.1474747
更新日期：2018-08-01 00:00:00
abstract：OBJECTIVE:Cost-effectiveness analyses of new treatments for cardiovascular disease frequently require input parameters whose values are known with uncertainty due to limited data. The objective of this paper is to examine the extent to which published sensitivity analyses addressing this uncertainty adhere to Health Te...
journal_title：Journal of medical economics
pub_type： 杂志文章,评审
doi：10.3111/13696990903123813
更新日期：2009-06-01 00:00:00
